Interleukin 7 and thymic stromal lymphopoietin: From immunity to leukemia

Noa Tal, Chen Shochat, Ifat Geron, Dani Bercovich, Shai Izraeli*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Cancer is often caused by deregulation of normal developmental processes. Here, we review recent research on the aberrant activation of two hematopoietic cytokine receptors in acute lymphoid leukemias. Somatic events in the genes for thymic stromal lymphopoietin and Interleukin 7 receptors as well as in their downstream JAK kinases result in constitutive ligand-independent activation of survival and proliferation in B and T lymphoid precursors. Drugs targeting these receptors or the signaling pathways might provide effective therapies of these leukemias.

Original languageEnglish
Pages (from-to)365-378
Number of pages14
JournalCellular and Molecular Life Sciences
Issue number3
StatePublished - Feb 2014


FundersFunder number
Waxman Cancer Foundation
Israel Cancer Research Fund
Swiss Re Foundation
Israel Science Foundation


    • CRLF2
    • IL7 receptor alpha
    • JAK1
    • JAK2
    • Leukemia
    • Thymic stromal lymphopoietin


    Dive into the research topics of 'Interleukin 7 and thymic stromal lymphopoietin: From immunity to leukemia'. Together they form a unique fingerprint.

    Cite this